Jupiter Life Line [JLHL] vs Wockhardt [WOCKPHARMA] Detailed Stock Comparison
Jupiter Life Line
NSE
Loading...
Wockhardt
NSE
Loading...
TLDR: Quick Comparison Summary
Based on 20 vital metrics comparison: Jupiter Life Line wins in 15 metrics, Wockhardt wins in 4 metrics, with 0 ties. Jupiter Life Line appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | Jupiter Life Line | Wockhardt | Better |
|---|---|---|---|
| P/E Ratio (TTM) | 51.91 | -494.04 | Wockhardt |
| Price-to-Book Ratio | 7.35 | 5.75 | Wockhardt |
| Debt-to-Equity Ratio | 28.99 | 43.40 | Jupiter Life Line |
| PEG Ratio | -32.09 | -1.02 | Jupiter Life Line |
| EV/EBITDA | 32.68 | 74.28 | Jupiter Life Line |
| Profit Margin (TTM) | 14.60% | -4.05% | Jupiter Life Line |
| Operating Margin (TTM) | 16.37% | 6.10% | Jupiter Life Line |
| EBITDA Margin (TTM) | 16.37% | 6.10% | Jupiter Life Line |
| Return on Equity | 14.27% | -1.01% | Jupiter Life Line |
| Return on Assets (TTM) | 10.16% | -0.58% | Jupiter Life Line |
| Free Cash Flow (TTM) | $-674.22M | $-3.87B | Jupiter Life Line |
| Dividend Yield | 0.13% | N/A | N/A |
| 1-Year Return | 4.74% | 54.61% | Wockhardt |
| Price-to-Sales Ratio (TTM) | 7.55 | 8.12 | Jupiter Life Line |
| Enterprise Value | $97.62B | $272.22B | Wockhardt |
| EV/Revenue Ratio | 7.39 | 8.97 | Jupiter Life Line |
| Gross Profit Margin (TTM) | 80.33% | 64.23% | Jupiter Life Line |
| Revenue per Share (TTM) | $206 | $189 | Jupiter Life Line |
| Earnings per Share (Diluted) | $29.30 | $-8.92 | Jupiter Life Line |
| Beta (Stock Volatility) | 0.77 | 1.25 | Jupiter Life Line |
Performance
News Sentiment
Key Stats
Valuation
Financials
Short Interest
Dividends
Jupiter Life Line vs Wockhardt Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| Jupiter Life Line | -1.14% | -1.22% | 4.30% | 1.30% | -3.96% | -1.95% |
| Wockhardt | -2.20% | 0.18% | 5.45% | -11.01% | 3.10% | 2.55% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Jupiter Life Line | 4.74% | 41.03% | 41.03% | 41.03% | 41.03% | 41.03% |
| Wockhardt | 54.61% | 488.76% | 370.91% | -3.64% | 343.96% | 198.89% |
News Based Sentiment: Jupiter Life Line vs Wockhardt
Jupiter Life Line
News based Sentiment: POSITIVE
September was a pivotal month for Jupiter Life Line Hospitals, characterized by a crucial regulatory approval for the Medulla merger, solid Q2 financial results, and a notable increase in investor interest. These developments collectively strengthen the investment case and suggest continued positive momentum for the company.
Wockhardt
News based Sentiment: MIXED
Wockhardt experienced both positive developments – a landmark FDA submission and a tariff clarification – alongside continued financial losses. The increase in FII/FPI investment suggests growing interest, but the stock's performance and overall financial picture remain mixed, making this a significant but complex month for the company.
Performance & Financial Health Analysis: Jupiter Life Line vs Wockhardt
| Metric | JLHL | WOCKPHARMA |
|---|---|---|
| Market Information | ||
| Market Cap | ₹100.42B | ₹271.69B |
| Market Cap Category | Mid cap | Large cap |
| 10 Day Avg. Volume | 54,273 | 1,627,195 |
| 90 Day Avg. Volume | 34,266 | 738,600 |
| Last Close | ₹1,483.20 | ₹1,460.00 |
| 52 Week Range | ₹1,266.00 - ₹1,770.00 | ₹915.00 - ₹1,868.80 |
| % from 52W High | -16.20% | -21.88% |
| All-Time High | ₹1,770.00 (Mar 24, 2025) | ₹2,168.80 (Mar 11, 2013) |
| % from All-Time High | -16.20% | -32.68% |
| Growth Metrics | ||
| Quarterly Revenue Growth | 0.21% | 0.00% |
| Quarterly Earnings Growth | -0.02% | 0.00% |
| Financial Health | ||
| Profit Margin (TTM) | 0.15% | -0.04% |
| Operating Margin (TTM) | 0.16% | 0.06% |
| Return on Equity (TTM) | 0.14% | -0.01% |
| Debt to Equity (MRQ) | 28.99 | 43.40 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | ₹206.85 | ₹263.84 |
| Cash per Share (MRQ) | ₹91.96 | ₹36.19 |
| Operating Cash Flow (TTM) | ₹2.61B | ₹-2,910,000,000 |
| Levered Free Cash Flow (TTM) | ₹1.94B | ₹-470,000,000 |
| Dividends | ||
| Last 12-Month Dividend Yield | 0.13% | N/A |
| Last 12-Month Dividend | ₹2.00 | ₹0.00 |
Valuation & Enterprise Metrics Analysis: Jupiter Life Line vs Wockhardt
| Metric | JLHL | WOCKPHARMA |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | 51.91 | -494.04 |
| Forward P/E | 39.60 | N/A |
| PEG Ratio | -32.09 | -1.02 |
| Price to Sales (TTM) | 7.55 | 8.12 |
| Price to Book (MRQ) | 7.35 | 5.75 |
| Market Capitalization | ||
| Market Capitalization | ₹100.42B | ₹271.69B |
| Enterprise Value | ₹97.62B | ₹272.22B |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | 7.39 | 8.97 |
| Enterprise to EBITDA | 32.68 | 74.28 |
| Risk & Other Metrics | ||
| Beta | 0.77 | 1.25 |
| Book Value per Share (MRQ) | ₹206.85 | ₹263.84 |
Financial Statements Comparison: Jupiter Life Line vs Wockhardt
Financial Metrics
Loading Financial Charts...
Revenue
EBITDA
Operating Margin
Free Cash Flow
Long Term Debt
Profit Margin
Current Ratio
Operating Cash Flow
Income Statement (MRQ)
| Metric (MRQ) | JLHL | WOCKPHARMA |
|---|---|---|
| Revenue/Sales | ₹3.48B | ₹7.38B |
| Cost of Goods Sold | ₹683.62M | ₹2.64B |
| Gross Profit | ₹2.79B | ₹4.74B |
| Research & Development | N/A | N/A |
| Operating Income (EBIT) | ₹569.20M | ₹450.00M |
| EBITDA | ₹909.91M | ₹-50.00M |
| Pre-Tax Income | ₹615.32M | ₹-1.09B |
| Income Tax | ₹176.57M | ₹-10.00M |
| Net Income (Profit) | ₹438.75M | ₹-1.08B |
Balance Sheet & Liquidity Metrics (MRQ)
| Metric (MRQ) | JLHL | WOCKPHARMA |
|---|---|---|
| Cash & Equivalents | ₹3.68B | ₹1.12B |
| Total Current Assets | ₹6.87B | ₹25.69B |
| Total Current Liabilities | ₹1.52B | ₹20.42B |
| Long-Term Debt | ₹3.84B | ₹13.06B |
| Total Shareholders Equity | ₹13.56B | ₹46.57B |
| Retained Earnings | ₹5.52B | ₹1.88B |
| Property, Plant & Equipment | ₹3.64B | ₹970.00M |
Cash Flow Statement Comparison (MRQ)
| Metric (MRQ) | JLHL | WOCKPHARMA |
|---|---|---|
| Operating Cash Flow | N/A | N/A |
| Capital Expenditures | N/A | N/A |
| Free Cash Flow | N/A | N/A |
| Debt Repayment | N/A | N/A |
| Common Stock Repurchase | N/A | N/A |
Short Interest & Institutional Ownership Analysis
| Metric | JLHL | WOCKPHARMA |
|---|---|---|
| Shares Short | N/A | N/A |
| Short Ratio | N/A | N/A |
| Short % of Float | N/A | N/A |
| Average Daily Volume (10 Day) | 54,273 | 1,627,195 |
| Average Daily Volume (90 Day) | 34,266 | 738,600 |
| Shares Outstanding | 65.57M | 162.49M |
| Float Shares | 25.53M | 79.46M |
| % Held by Insiders | 0.66% | 0.51% |
| % Held by Institutions | 0.20% | 0.13% |
Dividend Analysis & Yield Comparison: Jupiter Life Line vs Wockhardt
| Metric | JLHL | WOCKPHARMA |
|---|---|---|
| Last 12-Month Dividend | ₹2.00 | ₹0.00 |
| Last 12-Month Dividend Yield | 0.13% | N/A |
| 3-Year Avg Annual Dividend | ₹0.67 | ₹0.00 |
| 3-Year Avg Dividend Yield | 0.08% | N/A |
| 3-Year Total Dividends | ₹2.00 | ₹0.00 |
| Ex-Dividend Date | Jul 04, 2025 | N/A |